Iovance Biotherapeutics Inc (IOVA):企業の財務・戦略的SWOT分析

◆英語タイトル:Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C3060
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Iovance Biotherapeutics Inc (IOVA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers. It develops products based on tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidate, LN-144 is an autologous, ready-to-infuse cell therapy. The product is an adoptive cell therapy using TIL technology and is being investigated in Phase II trials for treating patients with metastatic melanoma, recurrent and metastatic squamous cell carcinoma of the neck and head and recurrent and metastatic or persistent cervical cancer. The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.

Iovance Biotherapeutics Inc Key Recent Developments

Aug 06,2018: Iovance Biotherapeutics reports second quarter 2018 financial results and provides corporate update
May 11,2018: RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics
May 10,2018: Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
Mar 12,2018: Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
Mar 01,2018: Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Iovance Biotherapeutics Inc – Key Facts 6
Iovance Biotherapeutics Inc – Key Employees 7
Iovance Biotherapeutics Inc – Key Employee Biographies 8
Iovance Biotherapeutics Inc – Major Products and Services 9
Iovance Biotherapeutics Inc – History 10
Iovance Biotherapeutics Inc – Company Statement 11
Iovance Biotherapeutics Inc – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 13
Company Overview 13
Iovance Biotherapeutics Inc – Business Description 14
Iovance Biotherapeutics Inc – Corporate Strategy 15
Iovance Biotherapeutics Inc – SWOT Analysis 16
SWOT Analysis – Overview 16
Iovance Biotherapeutics Inc – Strengths 16
Iovance Biotherapeutics Inc – Weaknesses 17
Iovance Biotherapeutics Inc – Opportunities 18
Iovance Biotherapeutics Inc – Threats 19
Iovance Biotherapeutics Inc – Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios – Capital Market Ratios 21
Financial Ratios – Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios – Interim Ratios 25
Financial Ratios – Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Iovance Biotherapeutics Inc, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
Aug 06, 2018: Iovance Biotherapeutics reports second quarter 2018 financial results and provides corporate update 30
May 11, 2018: RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics 32
May 10, 2018: Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 33
Mar 12, 2018: Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update 35
Mar 01, 2018: Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors 37
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 38
Dec 13, 2017: BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics 39
Dec 13, 2017: Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017 40
Oct 31, 2017: Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results 41
Sep 07, 2017: Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center 44
Section 6 – Appendix 45
Methodology 45
Ratio Definitions 45
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Iovance Biotherapeutics Inc, Key Facts 6
Iovance Biotherapeutics Inc, Key Employees 7
Iovance Biotherapeutics Inc, Key Employee Biographies 8
Iovance Biotherapeutics Inc, Major Products and Services 9
Iovance Biotherapeutics Inc, History 10
Iovance Biotherapeutics Inc, Other Locations 12
Iovance Biotherapeutics Inc, Subsidiaries 12
Iovance Biotherapeutics Inc, Key Competitors 20
Iovance Biotherapeutics Inc, Ratios based on current share price 21
Iovance Biotherapeutics Inc, Annual Ratios 22
Iovance Biotherapeutics Inc, Annual Ratios (Cont...1) 23
Iovance Biotherapeutics Inc, Interim Ratios 25
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Iovance Biotherapeutics Inc, Recent Deals Summary 29
Currency Codes 45
Capital Market Ratios 45
Equity Ratios 46
Profitability Ratios 46
Cost Ratios 47
Liquidity Ratios 47
Leverage Ratios 48
Efficiency Ratios 48

List of Figures
Iovance Biotherapeutics Inc, Performance Chart (2013 - 2017) 24
Iovance Biotherapeutics Inc, Ratio Charts 26
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28

★海外企業調査レポート[Iovance Biotherapeutics Inc (IOVA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hexion Inc.:企業の戦略・SWOT・財務分析
    Hexion Inc. - Strategy, SWOT and Corporate Finance Report Summary Hexion Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • SGL Carbon SE:企業の戦略・SWOT・財務情報
    SGL Carbon SE - Strategy, SWOT and Corporate Finance Report Summary SGL Carbon SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • EXINI Diagnostics AB-医療機器分野:企業M&A・提携分析
    Summary EXINI Diagnostics AB (EXINI), a subsidiary of Progenics Pharmaceuticals Inc, is a healthcare IT company that offers development of software solutions for the medical diagnostic market. The company’s software solutions include EXINIbone, EXINIheart, EXINIbrain and EXINIdat. Its EXINIbone is u …
  • Colabor Group Inc (GCL):企業の財務・戦略的SWOT分析
    Colabor Group Inc (GCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • COWI AS:企業の戦略的SWOT分析
    COWI AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Seacor Holdings Inc (CKH):企業の財務・戦略的SWOT分析
    Summary Seacor Holdings Inc (Seacor) is a diversified holding company that offers domestic and international transportation, logistics and risk management consultancy services. The company offers ocean transportation and logistics services; inland transportation and logistics services; Witt O'Brien' …
  • GridPoint, Inc.:電力:M&Aディール及び事業提携情報
    Summary GridPoint, Inc. (GridPoint), a subsidiary of Twenty First Century Utilities LLC, is a smart buildings technology company. It provides visibility into facility operations, and assists customers to automate and control sites, lower energy spend, and manage day-to-day operations. The company pr …
  • Exponent Inc (EXPO):企業の財務・戦略的SWOT分析
    Summary Exponent Inc (Exponent), formerly Failure Analysis Associates Inc, is an engineering and scientific consulting company that provides technical solutions. The company provides engineering services in biomechanics, buildings and structures, biomedical engineering, civil engineering, electrical …
  • Ergon Inc:企業の戦略的SWOT分析
    Ergon Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Benitec Biopharma Ltd (BLT):医療機器:M&Aディール及び事業提携情報
    Summary Benitec Biopharma Ltd (Benitec) is a clinical stage biotechnology company. The company develops novel therapeutics for the treatment of chronic and life threatening diseases based on its proprietary gene silencing DNA directed RNA interference (ddRNAi) technology. It develops ddRNAi based th …
  • PPL Corporation:企業の戦略・SWOT・財務情報
    PPL Corporation - Strategy, SWOT and Corporate Finance Report Summary PPL Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Geokinetics Inc:企業の戦略的SWOT分析
    Geokinetics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Rafako SA (RFK):企業の財務・戦略的SWOT分析
    Rafako SA (RFK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Ocular Therapeutix Inc (OCUL):企業の財務・戦略的SWOT分析
    Summary Ocular Therapeutix Inc (Ocular Therapeutix), formerly I-Therapeutix Inc, is a biopharmaceutical company that discovers, develops and commercializes therapies for treating eye diseases. The company’s lead product candidate DEXTENZA is used for the treatment of post-surgical ocular inflammatio …
  • WuXi NextCODE Genomics:医療機器:M&Aディール及び事業提携情報
    Summary WuXi NextCODE Genomics USA Inc (WuXi NextCODE), a subsidiary of Wuxi Pharmatech (Cayman) Inc, is a genomic information company that offers competencies in generating, organizing, mining, sharing and applying genomic data. The company develops gene sequence analysis platform and database arch …
  • Endo International Plc (ENDP)-医療機器分野:企業M&A・提携分析
    Summary Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceutical products, generic pharmaceuticals and other products through its operating companies including Endo Pharmaceuticals, Paladin Labs, Par Pharmaceutical, …
  • Illovo Sugar Africa Pty Ltd:企業の戦略的SWOT分析
    Illovo Sugar Africa Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • TOWER Limited:企業の戦略・SWOT・財務情報
    TOWER Limited - Strategy, SWOT and Corporate Finance Report Summary TOWER Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Lebara Group:企業の戦略的SWOT分析
    Lebara Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Bracket Global LLC-製薬・医療分野:企業M&A・提携分析
    Summary Bracket Global LLC (Bracket Global) is pharmaceutical company that offers clinical research development services. It strives to bring together science, technology and service to provide superior clinical outcomes for pharmaceutical companies and patients. The company offers services such as …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆